Dynavax (NASDAQ:DVAX) jumps 31% premarket in reaction to its collaboration with Sinovac Biotech Ltd. (NASDAQ:SVA)
to develop a COVID-19 vaccine. Specifically, DVAX will contribute its
CpG 1018 adjuvant, used in hepatitis B vaccine Heplisav-B, while SVA
will contribute its coronavirus vaccine candidate.
An adjuvant is designed to boost the immune response thereby enhancing the effects of the vaccine.
Financial terms are not disclosed.
https://seekingalpha.com/news/3561220-dynavax-teams-up-sinovac-biotech-to-develop-covidminus-19-vaccine
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.